Kristopher L. Hanson - 20 May 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Reporting relationship: SVP and General Counsel
Issuer ticker: N/A
Reported as of: 20 May 2022
Net transaction value: +$3,291
SEC form: 4
Accepted by SEC: 24 May 2022, 17:13:29 UTC
Prior SEC filing: 28 Feb 2022
Next SEC filing: 27 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ John P. Sharp, Attorney-in-fact

Key filing fact

Kristopher L. Hanson filed Form 4 for PhaseBio Pharmaceuticals Inc on 24 May 2022.

Key facts

This page summarizes Kristopher L. Hanson's Form 4 filing for PhaseBio Pharmaceuticals Inc.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 May 2022, 17:13.

Change

Previous filing in this sequence was filed on 28 Feb 2022.
Current net transaction value: +$3,291.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHASQ transaction

Common Stock

Award

Transaction value: $3,291
Shares: +4,831
Change %: +133%
Price: $0.6813^*
Shares after: 8,463
Date: 20 May 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares were acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") in a transaction that is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

Footnote F2

In accordance with the ESPP provisions, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 20, 2022.